Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of DNL151 in Healthy Volunteers
NCT04557800Phase 1Completed
- Sponsor
- Denali Therapeutics Inc.
- Start
- Nov 2017
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Parkinson's disease (PD) comparing DNL151 with Placebo (2 arms). Primary endpoints: Incidence of treatment-emergent adverse events up to 42 days, Maximum observed concentration of DNL151 in plasma up to 42 days and 5 more. Started Nov 2017; status: completed.
02
Drugs
BIIB122
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04557800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04557800.